

Biophytis participates in the first Longevity Summit

Paris (France) and Cambridge (Massachusetts, United States), May 21, 2026 at 7.30 AM (CET) – Biophytis SA (Euronext Growth Paris: ALBPS), ("**Biophytis**" or the "**Company**"), a pioneer in the development of transformative therapies impacting longevity, announces its participation in the Longevity Summit 2026, held on May 20, 2026 at the French National Academy of Medicine in Paris, under the High Patronage of Emmanuel Macron, President of the French Republic.

The Longevity Summit 2026 is the first event in France entirely dedicated to the challenges of healthy longevity. It brings together nearly 150 public and private decision-makers, researchers, scientists, healthcare professionals, industrial players and representatives of French and international institutions to discuss advances in geroscience, artificial intelligence applied to healthcare, the prevention of pathological aging and the adaptation of healthcare systems to future demographic transformations.

The Summit's scientific committee notably includes several representatives from the IHU HealthAge in Toulouse, a longstanding partner of Biophytis, as well as experts from Columbia University, Stanford University, the Buck Institute for Research on Aging, Nature Aging, Inserm and numerous leading hospitals and institutions.

Biophytis' participation in this event reflects the Company's strategy to actively contribute to scientific and strategic discussions regarding the management of aging over the coming decades. The Company had the opportunity to present its therapeutic approach to longevity, focused on mobility, autonomy and the prevention of age-related muscle decline. Stanislas Veillet, Chairman and Chief Executive Officer of Biophytis, participated in roundtable discussions bringing together leading French and international experts to address the scientific, medical, economic and societal challenges associated with healthy aging.

* * *

About BIOPHYTIS

Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular diseases (sarcopenia, Phase 3 ready to start) and metabolic disorders (obesity, Phase 2 ready to start). The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. The Company's ordinary shares are listed on Euronext Growth Paris (ALBPS - FR001400OLP5) and its ADS (American Depositary Shares) are listed on the OTC market (BPTSY - US 09076G401). For more information, visit www.biophytis.com.

Disclaimer

This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties. The forward-looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements.

Please also refer to the "Risk and uncertainties the Company is to face" section from the Company's 2023 Financial Report available on BIOPHYTIS website (www.biophytis.com) and as exposed in the "Risk Factors" section of form 20-F as well as other forms filed with the SEC (Securities and Exchange Commission, USA). We undertake no obligation to publicly update or review any forward-looking statement, whether because of new information or otherwise, except as required by law.

Biophytis Contacts

Investor Relations

Investors@biophytis.com

Media contacts

Antoine Denry: antoine.denry@taddeo.fr – +33 6 18 07 83 27

Nizar Berrada : nizar.berrada@taddeo.fr - +33 6 38 31 90 50